Diroximelfumarat (1) – Vumerity®
Multiple Sclerosis (MS)
Characteristics
| Start date | 01.01.2022 |
|---|---|
| Resolution | 06.07.2023 |
| INN | Diroximelfumarat |
| Brand name | Vumerity® |
| Pharm. company | Biogen GmbH |
| G-BA Procedure ID | D-780 |
| ATC code | L04AX09 Other immunosuppressants (L04AX) |
| DDD | 0.92 g O |
| Therapeutic area | Nervous system diseases Multiple sclerosis (MS) / Neuromyelitis optica spectrum disorders (NMOSD) |
| Reason for procedure | not completed: discontinued |
| Specialty | Patent/data protection expired |
Associated procedures
<< List of all resolutions